| UNH |
Report |
Adjusted EPS |
BEAT |
pred ~$4.94 vs. cons $4.84 |
MEDIUM |
| UNH |
Report |
Revenue |
IN-LINE |
pred ~$110.9B vs. cons $110.7B |
MEDIUM |
| UNH |
Report |
Medical care ratio |
IN-LINE |
pred ~88.3% vs. cons 88.5% |
MEDIUM |
| UNH |
Guide |
FY26 adjusted EPS outlook |
LOWER |
guide ~$18.30 vs. cons $18.55 (FY26) |
MEDIUM |
| UNH |
Guide |
2H26 adjusted EPS implied by FY outlook |
LOWER |
guide ~$6.06 vs. cons $6.28 (2H26) |
MEDIUM |
| UNH |
Guide |
FY26 total medical-membership change |
UNCHANGED |
guide ~-1.3M vs. cons -1.3M (FY26) |
HIGH |
| UNH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| UNH |
Return |
5-day cumulative residual |
-4.0% (FOLLOW-THROUGH) |
A modest $0.10 EPS beat versus consensus is likely outweighed by FY26 guidance near $18.30 versus $18.55 consensus and lower implied 2H EPS of roughly $6.06 versus $6.28; out-period estimate cuts should persist after the initial reaction. |
MEDIUM |